On the basis of the model of hematopoietic reconstitution emerging from our recent clonal tracking data in humans6,41, we reasoned that the CD34+CD164high fraction might constitute a suitable self-sufficient cell product for transplantation that would not require the co-infusion of other cells to support recovery from neutropenia and early myelopoiesis. This evidence concerns the gene CD34 and neutropenia.